2. Insulet (Nasdaq:PODD): +83.1%Insulet is a major player when it comes to insulin pump therapy for diabetes. Billerica, Mass.–based Insulet touts its Omnipod system as an easy-to-use tubeless insulin pump. It provides up to three days of non-stop insulin delivery, and users don’t need to handle a needle. Investor demand for the company’s stock is so strong that Insulet announced in November that it was up-sizing a private placement to $350 million in convertible senior notes due in 2024, up from a previous $300 million.
You may also like: